Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 ...
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP ...
Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Emily Standley Allard on MSN
Top 10 coaches and mentors transforming lives in 2026
The most influential names this year aren’t simply offering strategies — they’re reshaping how individuals think, heal, earn, ...
FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January-December 2025 October-December 2025 Highlights Net sales totalled ...
The outlook for 2026 (provided on 14 January 2026): Net sales are estimated to be EUR 1,900 million to EUR 2,100 million. Operating profit is estimated to be EUR 550 million to EUR 750 million. Basic ...
Collaborative Alzheimer’s care improved quality of life and saved billions when scaled nationwide, outperforming the antiamyloid drug lecanemab, results of a new cost analysis suggest.
For some people, receiving therapy more frequently over a shorter period can lead to faster relief, better engagement, and ...
Culture isn’t vibes or slogans. It shapes performance, resists reinvention, and won’t change on your timeline, no matter how ...
If you’ve met one person with autism, you’ve met one person with autism. You want to find an assessment provider who recognizes the diversity of the autistic experience.
Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results